SCHEMBL19272295

SCHEMBL19272295

CC(C)c1cccc(C(C)C)c1NC(=O)NS(=O)(=O)N1C(C)COCC1C

nearest known ligand 0.62

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
▸ NLRP3 Q96P20 1/20 0.51
▸ GSTO1 P78417 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26975374 0.88 NLRP3 (0.51) NLRP3
SCHEMBL26975359 0.88 NLRP3 (0.51) NLRP3
SCHEMBL26975366 0.87 NLRP3 (0.43) NLRP3GSTO1
SCHEMBL31055724 0.86 NLRP3 (0.47) NLRP3GSTO1
SCHEMBL31055727 0.86 GSTO1 (0.44) NLRP3GSTO1
SCHEMBL26975362 0.81 NLRP3 (0.51) NLRP3
SCHEMBL26975368 0.80 NLRP3 (0.50) NLRP3
SCHEMBL26975364 0.79 NLRP3 (0.52) NLRP3
SCHEMBL26975372 0.78 NLRP3 (0.51) NLRP3
SCHEMBL26975371 0.78 NLRP3 (0.51) NLRP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3416948-B1 INDACENE BEARING SULFONYLUREAS AS ANTI-INFLAMMATORY AGENTS UNIV QUEENSLAND (AU) 2024-07-24 — — EP claimed
US-11858922-B2 Sulfonylureas and related compounds and use of same THE UNIVERSITY OF QUEENSLAND (AU) 2024-01-02 — — US disclosed
US-11858922-B2 Sulfonylureas and related compounds and use of same THE UNIVERSITY OF QUEENSLAND (AU) 2024-01-02 — — US disclosed
WO-2017140778-A1 SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME THE UNIVERSITY OF QUEENSLAND (AU) 2017-08-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11858922-B2 Sulfonylureas and related compounds and use of same NLRP3, NOD1, PYCARD NLRP3 1/4885GSTO1 1614/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback